Download PDF
Z Gastroenterol 2005; 43(3): 317-329
DOI: 10.1055/s-2004-813702
Übersicht

© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York

Antiangiogene Therapie gastrointestinaler Tumoren

Anti-angiogenic Therapy for Gastrointestinal TumoursF. Graepler1 , M. Gregor1 , U. M. Lauer1
  • 1Abteilung Innere Medizin I, Medizinische Universitätsklinik, Tübingen
F. Graepler und M. Gregor wurden durch die Deutsche Forschungsgemeinschaft (DFG), Sachbeihilfe G 1838 - 1/2, gefördert. Wir danken Herrn Hannes Schramm, Foto-Repro-Grafik-Abteilung des Universitätsklinikums Tübingen, für die grafische Gestaltung der Abbildungen.
Further Information

Publication History

manuskript received: 14.5.2004

manuscript accepted: 26.9.2004 manuscript accepted in revised version: 28.1.2005

Publication Date:
11 March 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Für die gastroenterologische Onkologie werden auf neuartigen Mechanismen basierende Therapiestrategien benötigt, die insbesondere keine Kreuzresistenzen mit den gegenwärtigen Standardtherapien zeigen. Einen solchen Ansatz stellt die therapeutisch intendierte Antiangiogenese dar, bei der zielgerichtet die Gefäßversorgung solider Tumoren inhibiert wird. Da sich zahlreiche gastrointestinale Tumoren durch eine ausgeprägte Neoangiogenese mit einer daraus resultierenden Hypervaskularisation auszeichnen, werden antiangiogene Therapieansätze künftig eine Schlüsselrolle in der gastroenterologischen Onkologie einnehmen. Entsprechend werden in dieser Übersichtsarbeit (i) grundlegende Mechanismen der Tumorangiogenese, (ii) aktuelle antiangiogene Interventionsansätze auf dem Gebiet der gastroenterologischen Onkologie sowie (iii) gegenwärtige Limitationen und Perspektiven dieser neuartigen Therapiestrategie dargestellt.

Abstract

New therapeutic strategies that notably lack cross resistance with established treatment regimens are much needed in gastroenterological oncology. One such approach is therapeutic anti-angiogenesis which aims at the inhibition of vasculature growth in solid tumours. Since numerous gastrointestinal tumours show strong tumour neoangiogenesis and consequently are highly vascularised, anti-angiogenic therapies will play a pivotal role in tomorrow’s gastroenterological oncology. Hence, this review covers (i) basic mechanisms of tumour angiogenesis, (ii) recent anti-angiogenic strategies in the field of gastroenterological oncology as well as (iii) a discussion of their current limitations and perspectives.

Schlüsselwörter

Tumorangiogenese - Antiangiogenese - antiangiogene Therapie - VEGF - Bevacizumab - gastroenterologische Tumortherapie

Key words

Tumour angiogenesis - anti-angiogenesis - anti-angiogenic therapy - VEGF - bevacizumab - gastrointestinal tumour therapy

Literatur

  • 1 Folkman J. Tumor angiogenesis: therapeutic implications.  N Engl J Med. 1971;  285 1182-1186
    CrossrefPubMedGoogle Scholar
  • 2 Fidler I J, Ellis L M. The implications of angiogenesis for the biology and therapy of cancer metastasis.  Cell. 1994;  79 185-188
    CrossrefPubMedGoogle Scholar
  • 3 Folkman J. Role of angiogenesis in tumor growth and metastasis.  Semin Oncol. 2002;  29 15-18
    PubMedGoogle Scholar
  • 4 Gimbrone M A Jr, Leapman S B, Cotran R S. et al . Tumor dormancy in vivo by prevention of neovascularization.  J Exp Med. 1972;  136 261-276
    CrossrefPubMedGoogle Scholar
  • 5 Benjamin L E, Golijanin D, Itin A. et al . Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.  J Clin Invest. 1999;  103 159-165
    CrossrefPubMedGoogle Scholar
  • 6 Kerbel R S. Tumor angiogenesis: past, present and the near future.  Carcinogenesis. 2000;  21 505-515
    CrossrefPubMedGoogle Scholar
  • 7 St Croix B, Rago C, Velculescu V. et al . Genes expressed in human tumor endothelium.  Science. 2000;  289 1197-1202
    CrossrefPubMedGoogle Scholar
  • 8 Cianchi F, Cortesini C, Bechi P. et al . Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer.  Gastroenterology. 2001;  121 1339-1347
    PubMedGoogle Scholar
  • 9 Li X M, Tang Z Y, Qin L X. et al . Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma.  J Exp Clin Cancer Res. 1999;  18 511-517
    PubMedGoogle Scholar
  • 10 Liu D H, Zhang X Y, Fan D M. et al . Expression of vascular endothelial growth factor and its role in oncogenesis of human gastric carcinoma.  World J Gastroenterol. 2001;  7 500-505
    PubMedGoogle Scholar
  • 11 Weidner N, Semple J P, Welch W R. et al . Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma.  N Engl J Med. 1991;  324 1-8
    CrossrefPubMedGoogle Scholar
  • 12 Frank R E, Saclarides T J, Leurgans S. et al . Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer.  Ann Surg. 1995;  222 695-699
    PubMedGoogle Scholar
  • 13 Takahashi Y, Kitadai Y, Bucana C D. et al . Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.  Cancer Res. 1995;  55 3964-3968
    PubMedGoogle Scholar
  • 14 Takebayashi Y, Aklyama S, Yamada K. et al . Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma.  Cancer. 1996;  78 226-231
    CrossrefPubMedGoogle Scholar
  • 15 Tomisaki S, Ohno S, Ichiyoshi Y. et al . Microvessel quantification and its possible relation with liver metastasis in colorectal cancer.  Cancer. 1996;  77 1722-1728
    PubMedGoogle Scholar
  • 16 Tanigawa N, Amaya H, Matsumura M. et al . Tumor angiogenesis and mode of metastasis in patients with colorectal cancer.  Cancer Res. 1997;  57 1043-1046
    PubMedGoogle Scholar
  • 17 Choi H J, Hyun M S, Jung G J. et al . Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence.  Oncology. 1998;  55 575-581
    PubMedGoogle Scholar
  • 18 Fox S H, Whalen G F, Sanders M M. et al . Angiogenesis in normal tissue adjacent to colon cancer.  J Surg Oncol. 1998;  69 230-234
    CrossrefPubMedGoogle Scholar
  • 19 Abdalla S A, Behzad F, Bsharah S. et al . Prognostic relevance of microvessel density in colorectal tumours.  Oncol Rep. 1999;  6 839-842
    PubMedGoogle Scholar
  • 20 Bachtiary B, Selzer E, Knocke T H. et al . Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival.  Cancer Lett. 2002;  179 197-203
    CrossrefPubMedGoogle Scholar
  • 21 Komuro H, Kaneko S, Kaneko M. et al . Expression of angiogenic factors and tumor progression in human neuroblastoma.  J Cancer Res Clin Oncol. 2001;  127 739-743
    PubMedGoogle Scholar
  • 22 Wu Y, Saldana L, Chillar R. et al . Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment.  Int J Oncol. 2002;  20 509-516
    PubMedGoogle Scholar
  • 23 Poon R T, Ng I O, Lau C. et al . Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study.  Ann Surg. 2001;  233 227-235
    CrossrefPubMedGoogle Scholar
  • 24 Boehm T, Folkman J, Browder T. et al . Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.  Nature. 1997;  390 404-407
    CrossrefPubMedGoogle Scholar
  • 25 Marmé D. The impact of anti-angiogenic agents on cancer therapy.  J Cancer Res Clin Oncol. 2003;  129 607-620
    PubMedGoogle Scholar
  • 26 Shalaby F, Rossant J, Yamaguchi T P. et al . Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice.  Nature. 1995;  376 62-66
    CrossrefPubMedGoogle Scholar
  • 27 Nissen N N, Polverini P J, Koch A E. et al . Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing.  Am J Pathol. 1998;  152 1445-1452
    PubMedGoogle Scholar
  • 28 Tonnesen M G, Feng X, Clark R A. Angiogenesis in wound healing.  J Investig Dermatol Symp Proc. 2000;  5 40-46
    PubMedGoogle Scholar
  • 29 Ross M A, Sander C M, Kleeb T B. et al . Spatiotemporal expression of angiogenesis growth factor receptors during the revascularization of regenerating rat liver.  Hepatology. 2001;  34 1135-1148
    CrossrefPubMedGoogle Scholar
  • 30 Shimizu H, Miyazaki M, Wakabayashi Y. et al . Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats.  J Hepatol. 2001;  34 683-689
    CrossrefPubMedGoogle Scholar
  • 31 Karuri A R, Kumar A M, Mukhopadhyay D. Differential expression and selective localization of vascular permeability factor/vascular endothelial growth factor in the rat uterus during the estrous cycle.  J Endocrinol. 1998;  159 489-499
    PubMedGoogle Scholar
  • 32 Krüssel J S, Casan E M, Raga F. et al . Expression of mRNA for vascular endothelial growth factor transmembraneous receptors Flt1 and KDR, and the soluble receptor sflt in cycling human endometrium.  Mol Hum Reprod. 1999;  5 452-458
    CrossrefPubMedGoogle Scholar
  • 33 Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.  Semin Oncol. 2002;  29 10-14
    PubMedGoogle Scholar
  • 34 von Marschall Z, Cramer T, Hocker M. et al . Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma.  Gut. 2001;  48 87-96
    CrossrefPubMedGoogle Scholar
  • 35 Arbiser J L, Moses M A, Fernandez C A. et al . Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways.  Proc Natl Acad Sci U S A. 1997;  94 861-866
    CrossrefPubMedGoogle Scholar
  • 36 Petit A M, Rak J, Hung M C. et al . Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.  Am J Pathol. 1997;  151 1523-1530
    PubMedGoogle Scholar
  • 37 Okada F, Rak J W, St C roix B. et al . Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells.  Proc Natl Acad Sci U S A. 1998;  95 3609-3614
    CrossrefPubMedGoogle Scholar
  • 38 Niklinska W, Burzykowski T, Chyczewski L. et al . Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis.  Lung Cancer. 2001;  34 (Suppl 2) S59-64
    CrossrefPubMedGoogle Scholar
  • 39 Yuan A, Yu C J, Luh K T. et al . Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer.  J Clin Oncol. 2002;  20 900-910
    PubMedGoogle Scholar
  • 40 Presta L G, Chen H, O’Connor S J. et al . Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.  Cancer Res. 1997;  57 4593-4599
    PubMedGoogle Scholar
  • 41 Kabbinavar F, Hurwitz H I, Fehrenbacher L. et al . Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.  J Clin Oncol. 2003;  21 60-65
    CrossrefPubMedGoogle Scholar
  • 42 Hurwitz H, Fehrenbacher L, Novotny W. et al . Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer.  N Engl J Med. 2004;  350 2335-2342
    CrossrefPubMedGoogle Scholar
  • 43 Shen B Q, Lee D Y, Zioncheck T F. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway.  J Biol Chem. 1999;  274 33 057-33 063
    PubMedGoogle Scholar
  • 44 Ostendorf T, Kunter U, Eitner F. et al . VEGF(165) mediates glomerular endothelial repair.  J Clin Invest. 1999;  104 913-923
    CrossrefPubMedGoogle Scholar
  • 45 Sugimoto H, Hamano Y, Charytan D. et al . Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria.  J Biol Chem. 2003;  278 12 605-12 608
    PubMedGoogle Scholar
  • 46 Giantonio B J, Levy D, O’Dwyer P J. et al .Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): Updated results from the Eastern Cooperative Oncology Group (ECOG) Study E2200. ASCO Gastrointestinal Cancers Symposium 2004, Abstr. 289, http://www.asco.org/ac/1,1003,_12-002643-00_18-0027-00_19-00507,00.asp. 
    Google Scholar
  • 47 Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin.  J Clin Oncol. 2003;  21 3542
    CrossrefPubMedGoogle Scholar
  • 48 Giantonio B J, Catalano P J, Meropol N J. et al .The addition of bevacizumab (anti-VEGF) to FOLFOX4 in previously treated advanced colorectal cancer (advCRC): An updated interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. ASCO Gastrointestinal Cancers Symposium 2004, Abstr. 241, http://www.asco.org/ac/1,1003,_12-002643-00_18-0027-00_19-00554,00.asp. 
    Google Scholar
  • 49 Jones M K, Kawanaka H, Baatar D. et al . Gene therapy for gastric ulcers with single local injection of naked DNA encoding VEGF and angiopoietin-1.  Gastroenterology. 2001;  121 1040-1047
    PubMedGoogle Scholar
  • 50 Economides A N, Carpenter L R, Rudge J S. et al . Cytokine traps: multi-component, high-affinity blockers of cytokine action.  Nat Med. 2003;  9 47-52
    PubMedGoogle Scholar
  • 51 Holash J, Davis S, Papadopoulos N. et al . VEGF-Trap: a VEGF blocker with potent antitumor effects.  Proc Natl Acad Sci U S A. 2002;  99 11 393-11 398
    PubMedGoogle Scholar
  • 52 Byrne A T, Ross L, Holash J. et al . Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.  Clin Cancer Res. 2003;  9 5721-5728
    PubMedGoogle Scholar
  • 53 Huang J, Frischer J S, Serur A. et al . Regression of established tumors and metastases by potent vascular endothelial growth factor blockade.  Proc Natl Acad Sci U S A. 2003;  100 7785-7790
    CrossrefPubMedGoogle Scholar
  • 54 Kim E S, Serur A, Huang J. et al . Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma.  Proc Natl Acad Sci U S A. 2002;  99 11 399-11 404
    PubMedGoogle Scholar
  • 55 Wood J M, Bold G, Buchdunger E. et al . PTK787/ZK 222 584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.  Cancer Res. 2000;  60 2178-2189
    PubMedGoogle Scholar
  • 56 Drevs J, Mross K, Fuxius S. et al .A phase-1 dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor-inhibitor PTK787/ZK222584 (PTK/ZK) in patients with liver metastasis of advanced cancer. ASCO Annual Meeting 2001, Proc ASCO 2001;20:398. http://www.asco.org/ac/1,1003,_12-002643-00_18-0010-00_19-00398,00.asp. 
    Google Scholar
  • 57 George D, Jonasch E, Hart L. et al . A phase I, dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor inhibitor PTK787/ZK 222 584 (PTK/ZK) in patients with advanced renal cell or prostate carcinomas.  Proc AACR. 2002;  43 548
    PubMedGoogle Scholar
  • 58 Morgan B, Thomas A L, Drevs J. et al . Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222 584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.  J Clin Oncol. 2003;  21 3955-3964
    CrossrefPubMedGoogle Scholar
  • 59 O’Reilly M S, Holmgren L, Shing Y. et al . Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.  Cell. 1994;  79 315-328
    CrossrefPubMedGoogle Scholar
  • 60 O’Reilly M S, Boehm T, Shing Y. et al . Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.  Cell. 1997;  88 277-285
    CrossrefPubMedGoogle Scholar
  • 61 Bagavandoss P, Wilks J W. Specific inhibition of endothelial cell proliferation by thrombospondin.  Biochem Biophys Res Commun. 1990;  170 867-872
    CrossrefPubMedGoogle Scholar
  • 62 Armstrong L C, Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis.  Matrix Biol. 2003;  22 63-71
    CrossrefPubMedGoogle Scholar
  • 63 Holmgren L, O’Reilly M S, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.  Nat Med. 1995;  1 149-153
    PubMedGoogle Scholar
  • 64 Folkman J, Kalluri R. Cancer without disease.  Nature. 2004;  427 787
    CrossrefPubMedGoogle Scholar
  • 65 Dhar D K, Ono T, Yamanoi A. et al . Serum endostatin predicts tumor vascularity in hepatocellular carcinoma.  Cancer. 2002;  95 2188-2195
    CrossrefPubMedGoogle Scholar
  • 66 Musso O, Rehn M, Theret N. et al . Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas.  Cancer Res. 2001;  61 45-49
    PubMedGoogle Scholar
  • 67 Ferreras M, Felbor U, Lenhard T. et al . Generation and degradation of human endostatin proteins by various proteinases.  FEBS Lett. 2000;  486 247-251
    CrossrefPubMedGoogle Scholar
  • 68 Schuppan D, Cramer T, Bauer M. et al . Hepatocytes as a source of collagen type XVIII endostatin.  Lancet. 1998;  352 879-880
    CrossrefPubMedGoogle Scholar
  • 69 Mundhenke C, Thomas J P, Wilding G. et al . Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin.  Clin Cancer Res. 2001;  7 3366-3374
    PubMedGoogle Scholar
  • 70 Herbst R S, Hess K R, Tran H T. et al . Phase I study of recombinant human endostatin in patients with advanced solid tumors.  J Clin Oncol. 2002;  20 3792-3803
    CrossrefPubMedGoogle Scholar
  • 71 Eder J P Jr, Supko J G, Clark J W. et al . Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily.  J Clin Oncol. 2002;  20 3772-3784
    CrossrefPubMedGoogle Scholar
  • 72 Thomas J P, Arzoomanian R Z, Alberti D. et al . Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors.  J Clin Oncol. 2003;  21 223-231
    CrossrefPubMedGoogle Scholar
  • 73 Kulke M, Bergsland E, Ryan D P. et al .A phase II, open-label, safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors. ASCO Annual Meeting 2003, Abstr. 958, Proc Am Soc Clin Oncol. 2003;22:239. http://www.asco.org/ac/1,1003,_12-002643-00_18-0023-00_19-00103748,00.asp. 
    Google Scholar
  • 74 Davis D W, Shen Y, Mullani N A. et al . Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors.  Clin Cancer Res. 2004;  10 33-42
    PubMedGoogle Scholar
  • 75 Gately S, Li W W. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.  Semin Oncol. 2004;  31 2-11
    PubMedGoogle Scholar
  • 76 Scavelli C, Vacca A, Di Pietro G. et al . Crosstalk between angiogenesis and lymphangiogenesis in tumor progression.  Leukemia. 2004;  18 1054-1058
    CrossrefPubMedGoogle Scholar
  • 77 Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis.  Physiol Rev. 2002;  82 673-700
    PubMedGoogle Scholar
  • 78 Kitadai Y, Onogawa S, Kuwai T. et al . Angiogenic switch occurs during the precancerous stage of human esophageal squamous cell carcinoma.  Oncol Rep. 2004;  11 315-319
    PubMedGoogle Scholar
  • 79 Patel T, Roychowdhury D, Chadalavada R. Angiogenesis in Esophageal Cancer. ASCO Annual Meeting 1999, Abstr. 2373, http://www.asco.org/ac/1,1003,_12-002643-00_18-0017-00_19-0016620,00.asp. 
    Google Scholar
  • 80 Millikan K W, Mall J W, Myers J A. et al . Do angiogenesis and growth factor expression predict prognosis of esophageal cancer?.  Am Surg. 2000;  66 401-405
    PubMedGoogle Scholar
  • 81 Du J R, Jiang Y, Zhang Y M. et al . Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinomas.  World J Gastroenterol. 2003;  9 1604-1606
    PubMedGoogle Scholar
  • 82 Wallner G, Ciechanski A, Dabrowski A. et al . Vascular endothelial growth factor and basic fibroblast growth factor in patients with squamous cell oesophageal cancer.  Folia Histochem Cytobiol. 2001;  39 Suppl 2 122-123
    PubMedGoogle Scholar
  • 83 Uchida S, Shimada Y, Watanabe G. et al . In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis.  Br J Cancer. 1998;  77 1704-1709
    PubMedGoogle Scholar
  • 84 Ogata Y, Fujita H, Yamana H. et al . Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: long-term follow-up study.  World J Surg. 2003;  27 584-589
    CrossrefPubMedGoogle Scholar
  • 85 McDonnell C O, Harmey J H, Bouchier-Hayes D J. et al . Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with oesophageal cancer.  Br J Surg. 2001;  88 1105-1109
    CrossrefPubMedGoogle Scholar
  • 86 McDonnell C O, Bouchier-Hayes D J, Toomey D. et al . Effect of neoadjuvant chemoradiotherapy on angiogenesis in oesophageal cancer.  Br J Surg. 2003;  90 1373-1378
    CrossrefPubMedGoogle Scholar
  • 87 Shimada H, Hoshino T, Okazumi S. et al . Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma.  Br J Cancer. 2002;  86 552-557
    CrossrefPubMedGoogle Scholar
  • 88 Auvinen M I, Sihvo E I, Ruohtula T. et al . Incipient angiogenesis in Barrett’s epithelium and lymphangiogenesis in Barrett’s adenocarcinoma.  J Clin Oncol. 2002;  20 2971-2979
    CrossrefPubMedGoogle Scholar
  • 89 Couvelard A, Paraf F, Gratio V. et al . Angiogenesis in the neoplastic sequence of Barrett’s oesophagus. Correlation with VEGF expression.  J Pathol. 2000;  192 14-18
    CrossrefPubMedGoogle Scholar
  • 90 Sihvo E I, Ruohtula T, Auvinen M I. et al . Simultaneous progression of oxidative stress and angiogenesis in malignant transformation of Barrett esophagus.  J Thorac Cardiovasc Surg. 2003;  126 1952-1957
    CrossrefPubMedGoogle Scholar
  • 91 Morales C P, Souza R F, Spechler S J. Hallmarks of cancer progression in Barrett’s oesophagus.  Lancet. 2002;  360 1587-1589
    CrossrefPubMedGoogle Scholar
  • 92 Kotoh T, Dhar D K, Masunaga R. et al . Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice.  Surgery. 1999;  125 536-544
    CrossrefPubMedGoogle Scholar
  • 93 Kakeji Y, Koga T, Sumiyoshi Y. et al . Clinical significance of vascular endothelial growth factor expression in gastric cancer.  J Exp Clin Cancer Res. 2002;  21 125-129
    PubMedGoogle Scholar
  • 94 Tanigawa N, Amaya H, Matsumura M. et al . Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas.  Cancer Res. 1996;  56 2671-2676
    PubMedGoogle Scholar
  • 95 Saito H, Tsujitani S, Kondo A. et al . Combined analysis of tumour neoangiogenesis and local immune response in advanced gastric carcinoma.  Oncol Rep. 1999;  6 459-463
    PubMedGoogle Scholar
  • 96 Elpek G O, Gelen T, Aksoy N H. et al . Microvessel count, proliferating cell nuclear antigen and Ki-67 indices in gastric adenocarcinoma.  Pathol Oncol Res. 2000;  6 59-64
    PubMedGoogle Scholar
  • 97 Erenoglu C, Akin M L, Uluutku H. et al . Angiogenesis predicts poor prognosis in gastric carcinoma.  Dig Surg. 2000;  17 581-586
    CrossrefPubMedGoogle Scholar
  • 98 Saito H, Tsujitani S. Angiogenesis, angiogenic factor expression and prognosis of gastric carcinoma.  Anticancer Res. 2001;  21 4365-4372
    PubMedGoogle Scholar
  • 99 Ichikura T, Tomimatsu S, Ohkura E. et al . Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma.  J Surg Oncol. 2001;  78 132-137
    CrossrefPubMedGoogle Scholar
  • 100 Kido S, Kitadai Y, Hattori N. et al . Interleukin 8 and vascular endothelial growth factor - prognostic factors in human gastric carcinomas?.  Eur J Cancer. 2001;  37 1482-1487
    CrossrefPubMedGoogle Scholar
  • 101 Kitadai Y, Sasaki A, Ito M. et al . Helicobacter pylori infection influences expression of genes related to angiogenesis and invasion in human gastric carcinoma cells.  Biochem Biophys Res Commun. 2003;  311 809-814
    CrossrefPubMedGoogle Scholar
  • 102 Zhong H, De Marzo A M, Laughner E. et al . Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.  Cancer Res. 1999;  59 5830-5835
    PubMedGoogle Scholar
  • 103 Shi Y H, Fang W G. Hypoxia-inducible factor-1 in tumour angiogenesis.  World J Gastroenterol. 2004;  10 1082-1087
    PubMedGoogle Scholar
  • 104 Chun Y S, Yeo E J, Choi E. et al . Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells.  Biochem Pharmacol. 2001;  61 947-954
    CrossrefPubMedGoogle Scholar
  • 105 Yeo E J, Chun Y S, Cho Y S. et al . YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.  J Natl Cancer Inst. 2003;  95 516-525
    CrossrefPubMedGoogle Scholar
  • 106 Kanai T, Konno H, Tanaka T. et al . Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice.  Int J Cancer. 1998;  77 933-936
    CrossrefPubMedGoogle Scholar
  • 107 Kamiya K, Konno H, Tanaka T. et al . Antitumor effect on human gastric cancer and induction of apoptosis by vascular endothelial growth factor neutralizing antibody.  Jpn J Cancer Res. 1999;  90 794-800
    PubMedGoogle Scholar
  • 108 Matsumoto K, Konno H, Tanaka T. et al . Combination therapy with vascular endothelial growth factor neutralizing antibody and mitomycin C on human gastric cancer xenograft.  Jpn J Cancer Res. 2000;  91 748-752
    PubMedGoogle Scholar
  • 109 Kitada T, Seki S, Sakaguchi H. et al . Clinicopathological significance of hypoxia-inducible factor-1alpha expression in human pancreatic carcinoma.  Histopathology. 2003;  43 550-555
    CrossrefPubMedGoogle Scholar
  • 110 Onizuka S, Kawakami S, Taniguchi K. et al . Pancreatic carcinogenesis: apoptosis and angiogenesis.  Pancreas. 2004;  28 317-319
    PubMedGoogle Scholar
  • 111 Kisker O, Onizuka S, Banyard J. et al . Generation of multiple angiogenesis inhibitors by human pancreatic cancer.  Cancer Res. 2001;  61 7298-7304
    PubMedGoogle Scholar
  • 112 Kisker O, Onizuka S, Becker C M. et al . Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice.  Neoplasia. 2003;  5 32-40
    PubMedGoogle Scholar
  • 113 Buchler P, Reber H A, Ullrich A. et al . Pancreatic cancer growth is inhibited by blockade of VEGF-RII.  Surgery. 2003;  134 772-782
    CrossrefPubMedGoogle Scholar
  • 114 Dobrzanski P, Hunter K, Jones-Bolin S. et al . Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist.  Cancer Res. 2004;  64 910-919
    CrossrefPubMedGoogle Scholar
  • 115 Yoshiji H, Kuriyama S, Yoshii J. et al . Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells.  Hepatology. 1998;  28 1489-1496
    CrossrefPubMedGoogle Scholar
  • 116 Park Y N, Kim Y B, Yang K M. et al . Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis.  Arch Pathol Lab Med. 2000;  124 1061-1065
    PubMedGoogle Scholar
  • 117 Ng I O, Poon R T, Lee J M. et al . Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma.  Am J Clin Pathol. 2001;  116 838-845
    CrossrefPubMedGoogle Scholar
  • 118 El-Assal O N, Yamanoi A, Soda Y. et al . Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver.  Hepatology. 1998;  27 1554-1562
    CrossrefPubMedGoogle Scholar
  • 119 Sun F X, Tang Z Y, Lui K D. et al . Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues.  Int J Cancer. 1996;  66 239-243
    CrossrefPubMedGoogle Scholar
  • 120 Graepler F, Verbeek B, Graeter T. et al .Combined antiangiogenic gene therapy with soluble VEGF receptor 1 (sFlt-1) and endostatin is highly effective in a rat model of HCC. Submitted. 
    Google Scholar
  • 121 Boedefeld W M II, Bland K I, Heslin M J. Recent Insights Into Angiogenesis, Apoptosis, Invasion, and Metastasis in Colorectal Carcinoma.  Ann Surg Oncol. 2003;  10 839-851
    CrossrefPubMedGoogle Scholar
  • 122 Simon R, Freidlin B, Rubinstein L. et al . Accelerated titration designs for phase I clinical trials in oncology.  J Natl Cancer Inst. 1997;  89 1138-1147
    CrossrefPubMedGoogle Scholar
  • 123 Brower V. Evidence of efficacy: researchers investigating markers for angiogenesis inhibitors.  J Natl Cancer Inst. 2003;  95 1425-1427
    PubMedGoogle Scholar
  • 124 Xie W, McCahon P, Jakobsen K. et al . Evaluation of the ability of digital infrared imaging to detect vascular changes in experimental animal tumours.  Int J Cancer. 2004;  108 790-794
    CrossrefPubMedGoogle Scholar
  • 125 Pahernik S, Harris A G, Schmitt-Sody M. et al . Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study.  Br J Cancer. 2002;  86 1622-1627
    CrossrefPubMedGoogle Scholar
  • 126 Herbst R S, Mullani N A, Davis D W. et al . Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.  J Clin Oncol. 2002;  20 3804-3814
    CrossrefPubMedGoogle Scholar
  • 127 Mancuso P, Calleri A, Cassi C. et al . Circulating endothelial cells as a novel marker of angiogenesis.  Adv Exp Med Biol. 2003;  522 83-97
    PubMedGoogle Scholar
  • 128 Berger A C, Feldman A L, Gnant M F. et al . The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing.  J Surg Res. 2000;  91 26-31
    CrossrefPubMedGoogle Scholar
  • 129 Abulafia O, Sherer D M. Angiogenesis of the endometrium.  Obstet Gynecol. 1999;  94 148-153
    CrossrefPubMedGoogle Scholar
  • 130 Ryan A M, Eppler D B, Hagler K E. et al . Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody.  Toxicol Pathol. 1999;  27 78-86
    PubMedGoogle Scholar
  • 131 Hull M L, Charnock-Jones D S, Chan C LK. et al . Antiangiogenic agents are effective inhibitors of endometriosis.  J Clin Endocrinol Metab. 2003;  88 2889-2899
    CrossrefPubMedGoogle Scholar
  • 132 Nap A W, Griffioen A W, Dunselman G AJ. et al . Antiangiogenesis therapy for endometriosis.  J Clin Endocrinol Metab. 2004;  89 1089-1095
    CrossrefPubMedGoogle Scholar
  • 133 Kerbel R S, Yu J, Tran J. et al . Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.  Cancer Metastasis Rev. 2001;  20 79-86
    CrossrefPubMedGoogle Scholar
  • 134 Yokoyama Y, Dhanabal M, Griffioen A W. et al . Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth.  Cancer Res. 2000;  60 2190-2196
    PubMedGoogle Scholar
  • 135 Scappaticci F A, Smith R, Pathak A. et al . Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice.  Mol Ther. 2001;  3 186-196
    CrossrefPubMedGoogle Scholar
  • 136 Scappaticci F A, Contreras A, Smith R. et al . Statin-AE: a novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity.  Angiogenesis. 2001;  4 263-268
    CrossrefPubMedGoogle Scholar
  • 137 Bergers G, Javaherian K, Lo K M. et al . Effects of angiogenesis inhibitors on multistage carcinogenesis in mice.  Science. 1999;  284 808-812
    CrossrefPubMedGoogle Scholar
  • 138 Hood J D, Cheresh D A. Building a better Trap.  Proc Natl Acad Sci U S A. 2003;  100 8624-8625
    CrossrefPubMedGoogle Scholar
  • 139 Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.  Cell. 1996;  86 353-364
    CrossrefPubMedGoogle Scholar
  • 140 Zorick T S, Mustacchi Z, Bando S Y. et al . High serum endostatin levels in Down syndrome: implications for improved treatment and prevention of solid tumours.  Eur J Hum Genet. 2001;  9 811-814
    PubMedGoogle Scholar
  • 141 Kerbel R S. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results.  J Clin Oncol. 2001;  19 45S-51S
    PubMedGoogle Scholar

1 http://www.boerse-online.de/v4/aktien/usa_asien/art/ac/262773.html

2 http://clinicaltrials.gov/ct/search?term=bevacizumab&submit=Search (NIH)

3 http://www.ecog.org/general/active_prot.html (ECOG)

4 http://www.eortc.be/protoc/ (EORTC)

5 http://www.studien.de/

6 http://www.regeneron.com/company/tarrytown.asp (Fa. Regeneron)

7 http://www.schering.de/scripts/de/30_rd/pipe/onco/conf12.php (Fa. Schering)

Dr. med. Florian Graepler

Abteilung Innere Medizin I, Medizinische Universitätsklinik, Universitätsklinikum Tübingen

Otfried-Müller-Straße 10

72076 Tübingen

Phone: ++ 49/70 71/2 98 06 51

Fax: ++ 49/70 71/29 46 30

Email: florian.graepler@uni-tuebingen.de

      >